Esophageal squamous cell carcinoma (ESCC) is the most common histological type in China. MicroRNAs are endogenously expressed in mammals and play a significant role in tumor invasion and metastasis by targeting potential downstream genes. In the present study, microarray analysis showed that miR-375 expression was distinctly downregulated in ESCC compared with that in normal esophageal epithelium tissues. Then, luciferase reporter assay showed that SHOX2 was the direct downstream target of miR-375 and this interaction was confirmed by the rescue experiments. Quantitative polymerase chain reaction results also showed that SHOX2 expression was upregulated in ESCC cells and tissues. Further analysis showed that SHOX2 induced proliferation, invasion, and metastasis of ESCC both in vivo and in vitro. Moreover, the interaction between miR-375 and SHOX2 affected the epithelial-to-mesenchymal transition. We conclude that miR-375 may suppress invasion and metastasis of ESCC by directly targeting SHOX2. The miR-375/SHOX2 axis may be a novel therapeutic target for ESCC.
Introduction
More than half of all esophageal cancers have been identified as esophageal squamous cell carcinoma (ESCC), which is the most common histological type in Asian countries [1] . ESCC has the eighth highest incidence and the sixth highest mortality rate among all cancers worldwide [2] . China is the highest-risk country [3] , and more than 90% of esophageal cancers are ESCCs, with most of them diagnosed at the advanced stage [4] . The prognosis is poor and the management of ESCC is difficult because of early aggressive metastasis to lymph nodes and organs [5] [6] [7] [8] .
MicroRNAs (miRNAs), which are small non-coding RNAs, are endogenously expressed in many organisms and can degrade or inhibit the expressions of target genes by base-pairing with their 3′-untranslated regions (3′-UTRs) [9] [10] [11] . Many studies have shown that miRNAs are vital in the etiology and pathology of tumorigenesis, including the epithelial-to-mesenchymal transition (EMT) [12] [13] [14] . Dysregulation of miRNAs plays an important role in numerous human pathological proliferation processes and in abnormal differentiation, morphogenesis, and tumorigenesis [5, 15] .
Metastasis of most epithelial cancer cells from primary organs to distant sites involves the transition from epithelial to mesenchymal features, which is known as EMT [16] . During EMT, epithelial cancer cells lose their original cell morphology and characteristics (conferred by E-cadherin and β-catenin) and acquire mesenchymal phenotype cell morphology and characteristics (conferred by Vimentin and N-cadherin) [16, 17] . EMT plays an important role in the beginning of metastasis in malignant cancers, which leads to poor clinical therapeutic effects and low overall survival [18] .
Recent studies have shown that miRNAs are closely involved in the processes of EMT-associated metastasis and tumor progression [19, 20] . For example, miR-205 and miR-200, which are members of a large family that includes miR-200a/miR-200b/miR-200c, miR-141, and miR-429, play a vital role in the process of influencing EMT [21, 22] . Other studies have shown that the miR-200 family can induce cells from EMT in bladder cancer [23] . It has also been shown that miR-155 and miR-29a are associated with the TGF-β signaling pathways in breast cancer [24, 25] . MiR-200a and miR-200b have been confirmed to inhibit ZEB1 and ZEB2, respectively [18] . MiR-630 was also identified to inhibit EMT process by targeting slug [26] . MiR-375 in breast cancer has been shown to influence EMT [27] .
Human short hox gene 2 (SHOX2), a homolog of the short stature homeobox (SHOX) gene, is a 10,000-bp member of the family of homolog heterotypes located at the long arm of chromosome 3 and is mainly involved in transcriptional regulation of the formation period of vertebrate embryos [28, 29] . SHOX2 plays a vital role in the development of bone, heart, and nervous system expression of mesoderm and ectoderm in the embryonic period [30] . In lung cancer, SHOX2 could be used as a biomarker for predicting the occurrence of cancers and distinguishing malignant from benign types [31] . A positive correlation between high expression of SHOX2 and primary hepatocellular carcinoma has been demonstrated [32] . Recently, SHOX2 was proven to be related to the occurrence and recurrence of breast cancer [33] .
Despite a large body of researches on the relationship between miRNAs and EMT, there have been few studies on ESCC. To elucidate the important underlying mechanisms of metastases, which is important for the development of therapeutic drugs, gene chip assay was performed and results showed that miR-375 expression was altered most conspicuously in ESCC. We speculated that miR-375 might act as a micromolecule that triggers EMT. We further explored the relationships among miR-375, SHOX2, and EMT to provide evidence to support a theoretical rationale for the treatment of ESCC. Our results suggested that miR-375 and SHOX2 were potent EMT regulators that significantly influenced ESCC both in vivo and in vitro.
Materials and Methods

Cell culture
Three strains of ESCC cell lines (KYSE70, ECA109, and EC9706) and the normal human esophageal epithelium cell line (HEEC) were purchased from the Fudan University Shanghai Cell Bank (Shanghai, China). Cells were cultured in RPMI 1640 with 10% fetal bovine serum (FBS) at 37°C under the condition of 5% CO 2 .
Plasmid construction and cell transfection
MiR-375 mimics (miR-375), control group (miR-NC), miR-375 inhibitor (anti-miR-375), and the control group inhibitor (anti-miR-NC) were synthesized by Genechem Company (Shanghai, China). SHOX2 (GenBank NM003030. 4)-overexpressing plasmid vector was purchased from the Genechem Company and named as SHOX2. SHOX2 short hairpin RNA plasmid vector constructed by Genechem Company was named as shSHOX2. All of the plasmids were confirmed by DNA sequence analysis. Cells were transfected with reagent Lipofectaminee 2000 (Invitrogen, Carlsbad, USA) in opti-DMEM or opti-RPMI 1640 according to manufacturer's instructions.
Tissue samples
Clinical ESCC and matched adjacent normal tissue samples were collected from patients with ESCC who underwent esophagectomy at Jinling Hospital of Nanjing in December 2015 and the patients were pathologically diagnosed with ESCC which were not subject to preoperative chemotherapy and/or radiotherapy. Signed consent forms were obtained from all patients and this study was approved by the Ethics Committee of Jiangsu Province Medical Association.
Microarray analysis
The platform was the Agilent Human miRNA Microarray, Release 21.0 (Design ID: BC13137). The total RNA was quantified by the NanoDrop ND-2000 (Thermo Scientific, Waltham, USA) and the RNA integrity was assessed using Agilent Bioanalyzer 2100 (Agilent Technologies). The sample labeling, microarray hybridization and washing were performed according to the manufacturer's standard protocols. Briefly, total RNAs were dephosphorylated, desaturated and labeled with Cyanine-3-CTP. After purification, the labeled RNAs were hybridized onto the microarray. After being washed, the arrays were scanned with the Agilent Scanner G2505C (Agilent Technologies). Feature Extraction software (version10.7.1.1; Agilent Technologies) was used to analyze array images to get the raw data. Genespring software (version 13.1; Agilent Technologies) was used to carry out the basic analysis with the raw data. The raw data were normalized with the quantile algorithm. Differentially expressed miRNAs were then identified through fold change as well as P-value calculated by using a two-sided t-test on a single miRNA basis. The ratios of the P-value < 0.05 were generally accepted as true.
RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNAs were extracted by using Trizol (TaKaRa, Dalian, China) according to the manufacturer's instructions. The primers are shown in the Table 1 . Then reverse transcription was performed at 42°C using RNA reverse transcription kit (Abm, Nanjing, China) for 15 min. SHOX2 and miR-375 were measured through relative fluorescence collection analysis using SYBR Green and a STEP ONE RT-PCR apparatus (Applied Biosystems, Foster, USA). GAPDH and U6 were used, respectively, as internal references.
Western blot analysis
Total protein was extracted from cells by using RIPA lysis buffer (Beyotime, Nanjing, China) and stored at −20°C until use. Protein concentration was determined by BCA Protein Quantitation Assay (Thermo, Waltham, USA). Protein samples were subject to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto PVDF membrane (Millipore, Boston, USA). Membrane was blocked and incubated with various primary antibodies, followed by incubation with the corresponding horseradish peroxidaseconjugated anti-rabbit IgG or anti-mouse IgG secondary antibody (Cell Signaling Technology, Beverly, USA), and finally visualized by using enhanced chemiluminescence kit. GAPDH was used as an internal reference. Primary antibodies used in the western blot analysis were anti-SHOX2 monoclonal antibody, anti-Vimentin antibody, anti-Ecadherin antibody, anti-N-cadherin antibody, anti-β-catenin antibody, and anti-GAPDH antibody, which were all purchased from Abcam (Cambridge, UK) and used at 1:1000 dilution.
MTT analysis
Cell proliferation was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded into 96-well plates with 4000 cells per well and cultured for 1-3 days. Then, 0.5 mg/ml of MTT solution (Sigma, St Louis, USA) was added to the cells and incubated for 4 h. After removing the medium at 24, 48, and 72 h, respectively, the remaining MTT formazan crystals were solubilized with 100 µl of DMSO (Sigma) and the optical density at 560 nm was measured with a microplate reader (BioTek, Beijing, China).
Colony formation analysis
After transfection, cells were placed in a 6-well plate and maintained in RPMI 1640 with 10% FBS at 37°C with 5% CO 2 . The medium was replaced every 48 h. The colonies were visible after 14 days of culture. The medium was removed and the cells were fixed with methanol and stained with 0.1% crystal violet. Crystal violet was carefully removed and the plates were immersed in ddH 2 O to rinse off crystal violet. After the plates were dried at room temperature, the number of colonies was manually counted.
Wound healing assay
Cells were seeded in 24-well plates and cultured. A germ-free plastic scriber was used to create 1.0-mm wounds. The cells were washed and incubated in serum-free medium for 48 h. The wound healing process was observed under a microscope (Leica, Wetzlar, Germany).
In vitro Transwell assays
Cell invasion was analyzed by using a Transwell chamber (8.0-μm pore size; 6.5-mm diameter; Corning, New York, USA). Cells were added into the upper chamber and cultured in serum-free RPMI 1640 for 24 h after transfection. Cells in the upper chambers were removed by using a wiper and cells invaded into the lower chambers were fixed with methanol and stained with 0.1% crystal violet. Then, five random fields were selected to record the bottom of the chamber of cells showing cell invasion and metastasis under a microscope. All experiments were performed at least three times in triplicate.
Luciferase reporter gene assay
To construct the SHOX2 3′-UTR luciferase reporter gene plasmid, polymerase chain reaction (PCR) was used to amplify this fragment containing putative binding sites for miR-375 by introducing a restriction enzyme site Sac at both SacI and HindIII using highfidelity enzyme (TOYOBO, Tokyo, Japan). The primers used were SHOX2 F: ATGAGCTCATTTCCCCCTCTCTATC; SHOX2 R: ATAAGCTTCAAAGCTCAACCGCATAC. Three plasmids, named as pmiR, pSHOX2-375-WT, and pSHOX2-375-mut, were subcloned into the downstream of the luciferase vector.
Cells were seeded in 96-well plates and co-transfected with 100 ng of pSHOX2-375-UTR-wt or pSHOX2-375-UTR-mut using 50 nM of Lipofectamine 2000. About 48 h after transfection, the cells were assayed by using a Dual-Glo Luciferase Assay System kit (Promega, Madison, USA) according to the manufacturer's instructions. The optical density measured with SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, USA).
The sequence of SHOX2 3′-UTR (405 bp) is shown in the Supplementary Materials.
In vivo tumor metastasis assay
Female nude BALB/c mice (6-week old, without thymus, average body weight 21 g) were purchased from the Department of Comparative Medicine (Jinling Hospital, Nanjing, China). Stable transfected cells were inoculated and allowed to grow exponentially, then split and grown in medium for 1 day. A total of 2.0 × 10 6 cells in 150 µl of physiological saline were subcutaneously injected into the skin of the abdomen flanks of nude mice under aseptic conditions. After 6 weeks, the nude mice were sacrificed and the subcutaneous tumors were removed. Tumor volume was calculated using the equation:
, where A is the largest diameter and B is the perpendicular diameter. The primary tumors were excised and analyzed by qPCR and western blot analysis. All animal studies were performed according to the protocols approved by the Jiangsu Province Experimental Animal Care and Use Committee.
Statistical analysis
All of the above experiments were repeated at least three times independently. Data were compared between groups using the MannWhitney U-test. Categorical variables were compared using the two sample tests or Fisher's exact test where appropriate. Differentially expressed miRNAs were calculated using a two-sided t-test. The results of in vitro migration assays and luciferase activities were compared using Student's t-test. All analyses were performed using SPSS17.0 statistical analysis software. Experimental data were reported as the mean ± standard deviation. P < 0.05 was considered to be statistically significant.
Results
MiR-375 expression was downregulated in ESCC tissues and ESCC cells
The miRNA expression profiles of normal esophageal epithelium tissues and esophageal squamous carcinoma tissues were determined by microarray analysis. Results showed that 2000 human miRNAs had various degrees of expression. In the fold-change analysis, 12 of the 2000 flagged miRNAs in tumor tissues had more than 2-fold alteration when compared with those in normal tissues ( Table 2) .
To confirm the microarray results, quantitative real-time PCR (qRT-PCR) analyses of the relative expression levels of miR-375, miR-630, miR-143-3p, miR-4419a, miR-133b, miR-143-5p, miR29c-3p, miR-4667-5p, miR-6131, miR-1183, miR-5703, and miR-4306 in ECA109 cells and HEEC cells were performed (Fig. 1A) . Five miRNAs (miR-375, miR-143-3p, miR-133b, miR-143-5p, and miR-29c-3p) were significantly downregulated in the ECA109 cells relative to those in the HEEC cells, whereas seven miRNAs (miR-630, miR-4419a, miR-4667-5p, miR-6131, miR-1183, miR-5703, and miR-4306) were significantly upregulated. The results of qRT-PCR analysis showed that those candidate miRNAs exhibited approximately similar patterns of upregulation or downregulation when compared with the microarray results, and miR-375 showed the greatest difference.
SHOX2 was verified as a direct target of miR-375 in ESCC cells
Identification of potential downstream targets of miRNAs is essential for investigating the biological functions on ESCC. Five target prediction tools (TargetScan, miRanda, miRTarget2, PITA, and PicTar) were used to predict and analyze the possible target of miR-375, and results showed that SHOX2 might be directly targeted by miR-375.
To investigate whether SHOX2 is a direct downstream target of miR-375, luciferase reporter assay was performed. Results showed that the relative luciferase activity of pSHOX2-375-WT+miR-375 was reduced by 90% relative to that of the negative controls; however, the luciferase activity of pSHOX2-375-mut was unaffected when simultaneously transfected with miR-375. These results showed that the putative miR-375 target was vital for the reduction of SHOX2 expression in ESCC cells (Fig. 1B) . Thus, SHOX2 might be a direct target of miR-375. qRT-PCR and western blot analysis showed that overexpression of miR-375 led to lower mRNA and protein expressions of SHOX2 in cells. These results indicated that SHOX2 expression could be negatively modulated by miR-375. Additionally, cells co-transfected with miR-375 and ectopic SHOX2 exhibited reverse SHOX2 mRNA and protein expressions (Fig. 1C,D) , which further suggested that SHOX2 was regulated by miR-375.
MiR-375 significantly inhibited proliferation, invasion and metastasis of ESCC cells, which could be reversed by SHOX2
Upregulation of miR-375 expression potently inhibited more than half of cells from proliferation, reduced the colony formation rate, and suppressed closure of scratched wounds, when compared with those in the negative control groups.
As demonstrated in the invasion assay, upregulation of miR-375 suppressed invasion by approximately 83%, 65%, and 65%, respectively, in three ESCC cell lines, when compared with the invasion in negative controls. These results showed that miR-375 conspicuously diminished the proliferative and metastatic capacities of ESCC cells.
Subsequently, MTT assay showed that co-transfection of miR-375 and SHOX2 into these three cell lines led to extremely high growth rates ( Fig. 2A) . Colony formation assay revealed that cells co-transfected with miR-375 and SHOX2 exhibited high colony formation rates (Fig. 2B) . Similarly, a reversion phenomenon occurred in the wound healing assay in cells exhibiting cooverexpression of miR-375 and SHOX2 cells (Fig. 2C) . Invasion assay showed that the cells co-transfected with miR-375 and SHOX2 also stimulated cell invasion (Fig. 2D) . Based on these results, we concluded that miR-375 directly targeted at and negatively regulated SHOX2.
The effects of SHOX2 on the biological behaviors of ESCC cells
The expression levels of SHOX2 in three ESCC cell lines and clinical samples were further detected and results showed that the expressions were significantly higher in cancers than in normal human esophageal epithelium tissues and cells (Fig. 3A,B) .
In addition, cells transfected with ectopic SHOX2 significantly transformed into a mesenchymal morphology (Fig. 3C) , which suggested that SHOX2 enhanced the invasive ability of ESCC.
MTT assay showed that cells with increased SHOX2 expression exhibited significantly increased proliferative ability, whereas cells with decreased SHOX2 expression exhibited decreased proliferative ability (Fig. 3D) . The colony formation assay showed that there was a nearly 2-fold increase in the cloning cluster number of cells transfected with SHOX2 relative to those transfected with NC, whereas one-third of the cells exhibited decreased expression of SHOX2 (Fig. 3E) . There was an approximately 1.5-fold increase in the number of cells with SHOX2 overexpression that invaded the bottom of the chamber, whereas there was more than a 50% decrease in the number of cells with decreased SHOX2 expression, as shown in the Transwell assay in vitro (Fig. 3F) . Wound healing assay also showed that cells with SHOX2 overexpression recovered quickly, whereas cells with decreased expression of SHOX2 recovered slowly relative to the control cells (Fig. 3G) . These results suggested that SHOX2 acts as an oncogene that induces proliferation, invasion, and metastasis of ESCC cells.
EMT was influenced by miR-375 and SHOX2 interaction in ESCC cells
The hypothesis that EMT is potentially regulated by miR-375 and SHOX2 interaction was propounded because of the transformation of morphology and the enhancement of invasion and metastasis on ESCC cells were regulated by miR-375 inhibitor or ectopic SHOX2. To prove this presumption, EMT markers in cells with stable ectopic miR-375 expression were examined. qPCR assay revealed that miR-375 maintained the morphology of cells undergoing EMT. Western blot analysis showed that miR-375 induced E-cadherin and β-catenin expressions but reduced N-cadherin and Vimentin expressions. These results showed a definite and unequivocal effect of miR-375 on abolishing EMT events.
The same assay was also performed to determine if SHOX2 could interact with miR-375. The results showed that β-catenin, E-cadherin, N-cadherin, and Vimentin mRNA and protein expressions were reversed by stable ectopic SHOX2 expression after transfection with miR-375 (Fig. 4A,B) . These results suggested that SHOX2 is regulated by miR-375 in the course of EMT.
Additionally, qPCR analysis showed that stable exogenous SHOX2 increased the expressions of N-cadherin and Vimentin mRNA, but decreased the expressions of E-cadherin and β-catenin mRNA. Knockdown of SHOX2 increased the expressions of E-cadherin and β-catenin mRNA, but decreased the expressions of N-cadherin and Vimentin mRNA (Fig. 4C) . Western blot analysis showed that overexpression of SHOX2 induced the expressions of N-cadherin and Vimentin proteins, but decreased the expressions of E-cadherin and β-catenin proteins, whereas decreased expression of SHOX2 induced the expressions of E-cadherin and β-catenin proteins, but decreased the expressions of N-cadherin and Vimentin proteins (Fig. 4D) . These results suggested that EMT is strongly influenced by SHOX2 in ESCC cells.
SHOX2 induced proliferation, invasion, and metastasis of carcinomas in athymic nude mice
Tumors in nude mice were generated by KYSE70 cells stably transfected with overexpressed SHOX2 and down-expressed SHOX2. Results showed that tumors with overexpressed SHOX2 had a higher growth rate than those of the negative controls. However, tumors with decreased expression of SHOX2 had a lower growth rate than those of the shControl (Fig. 5A) . Tumors derived from SHOX2-transfected ESCC cells grew more rapidly than those derived from negative control-transfected cells. However, tumors derived from shSHOX2-transfected ESCC cells grew more slowly than those derived from shControl-transfected cells (Fig. 5B) . Western blot analysis and qPCR assay indicated that the subcutaneous tumors generated with exogenous SHOX2 exhibited low expressions of Ecadherin and β-catenin but high expressions of N-cadherin and Vimentin relative to those of the negative controls, whereas tumors with SHOX2-knockdown exhibited high expressions of E-cadherin and β-catenin but low expressions of N-cadherin and Vimentin relative to those of the shControl (Fig. 5C,D) . These results showed that SHOX2 induced proliferation and metastasis of carcinomas and influenced the process of EMT in vivo.
Discussion
ESCC is the most common histological type of esophageal cancer in Asian countries [34, 35] . China and Japan are the highest-risk countries, and 90% of esophageal cancers are ESCCs [36] . Early diagnosis is insufficient, and prognosis remains poor despite recent clinical improvements in multimodality therapies for treatment of ESCC [37, 38] .
Intriguing evidence has suggested that changes of miRNAs provoke downstream genetic changes that influence the proliferation, invasion, and metastasis of ESCC [39, 40] . MiRNAs which are small non-coding RNAs of approximately 18-22 nucleotides are increasingly considered to play crucial roles in the proliferation and metastasis of malignancies [41, 42] . Li et al. [43] found that ARTN was a functional target of miR-223, the overexpression of which was shown to repress cell migration and invasion in human esophageal carcinoma cell lines. Ding et al. [44] revealed that miR-29c expression was downregulated in ESCC tissues and cells, a process that might play a significant role in malignant behavior of ESCC through regulating cyclin E. The functions of miR-143 with respect to ESCC are mediated by inhibition of extracellular signal-regulated kinase-5 activity [45] .
It is essential to identify a specific target for the treatment with ESCC to enable earlier diagnosis and clinical prognosis [46] . In this study, microarray analysis was used to identify and compare miRNA expression profiles between human ESCC and normal esophageal squamous tissues. The results showed that 12 of 2000 flagged miRNAs exhibited more than 2-fold expression changes in ESCC cells relative to the profiles in normal esophageal squamous tissues. The changes of the 12 miRNAs were then analyzed by qPCR analysis. The results showed that miR-375 exhibited the greatest change among the 12 miRNAs and suggested that miR-375 might be a diagnostic marker. This finding is consistent with that of Fu et al. [47] who previously reported that miR-375 expression was downregulated in ESCC and that this downregulation was a significant factor associated with poor prognosis in ESCC.
SHOX2, a homolog to the SHOX gene in humans [48] , was confirmed to be a direct downstream target of miR-375, which was consistent with the report by Hong et al. [33] . It was identified that the expressions of SHOX2 in ESCC tissues and cells were upregulated. Furthermore, MTT assay, colony formation assay, wound healing assay, and Transwell assay results showed that SHOX2 increased the proliferative, invasive, and metastatic abilities of ESCC. Nevertheless, these abilities were decreased when SHOX2 expression was downregulated, which indicated that SHOX2 was an oncogene in ESCC.
Because of the transformation of morphology, enhancement of invasion and metastasis in ESCC, EMT markers were measured by qPCR and western blot analysis, and results showed that miR-375 suppressed the process of EMT by diminishing SHOX2 expression. In contrast to miR-375, ectopic SHOX2 expression facilitated EMT both in vivo and in vitro. These results suggest that miR-375 blocks EMT by targeting SHOX2 in ESCC and that increased SHOX2 expression is an important step in the progression and metastasis of ESCC.
Nevertheless, there are several limitations in this study. Firstly, although miR-375 has been proven to target the SHOX2 gene and regulate biological activity in vivo and in vitro, other miRNAs that target SHOX2 may exist and should be identified in future studies. Secondly, the underlying mechanism of how SHOX2 influences EMT was not elucidated in this study. Thirdly, the correlation between SHOX2 expression and survival of patients in ESCC also was not determined. These problems should be addressed in future studies.
Taken together, our results showed that miR-375 and SHOX2 influenced ESCC tumorigenicity by controlling EMT in cells and nude mice. This newly identified mechanism underlying progression of metastasis may contribute to development of novel therapeutic strategies for patients. It is believed that miR-375/SHOX2 might be a novel target of drug therapy.
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